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Abstract
We describe a case of multiple myeloma (MM) and secondary plasma cell leukemia (PCL) secreting IgE-kappa
immunoglobulin. To our knowledge, only 2 cases of IgE-producing secondary PCL have been reported in the
medical literature. In our patient, the only tumor marker available for monitoring the therapeutic response to
chemotherapy and allogeneic stem cell transplantation was the quantitative M component at serum protein
electrophoresis (SPEP), because serum free light chains were in the normal range, Bence-Jones proteinuria was
absent, and quantitative serum IgE levels provided inaccurate and erratic results, due to the prozone effect. This is
a laboratory phenomenon that occurs when antigen excess interferes with antibody-based methods requiring
immune complex formation for detection. It is important to recognize the presence of a prozone effect, because it
can produce falsely normal results, and therefore it could lead clinicians to incorrect assessment of the response to
therapy.
Background
IgE myeloma is a very rare subtype of MM, and it repre-
sents < 0.01% of all plasma cell dyscrasias [1]. Since the
first case was described in 1967 [2], approximately 47
cases of IgE MM have been reported in the literature
[3-6]. IgE antibodies are named from the ragweed E anti-
gen, which was used for their isolation, and they are
involved in allergic responses, atopic conditions,
helminthic and respiratory infections, and chronic inflam-
matory diseases [7]. It is important to note that commonly
available serum immunofixation (IFE) testing screens only
for monoclonal IgG, IgM, and IgA chains. Therefore, IFE
specific for IgD and IgE should be requested when these
rare subtypes are suspected (e.g., when a monoclonal pro-
tein has been detected by SPEP, but routine IFE is nega-
tive). The clinical manifestations of IgE MM are similar to
those seen in other MM subtypes, but some experts con-
sider IgE MM an aggressive disease, associated with a sig-
nificantly higher rate of plasma cell leukemia [8,9]. Other
data do not support the aggressive nature of this subtype
of MM. A review of the first 19 reported cases of IgE MM
showed no difference in the incidence of extramedullary
plasma cell infiltration compared with other subtypes of
the disease [10].
We describe a case of IgE-kappa MM and secondary
PCL with falsely normal serum levels of IgE due to the
prozone effect.
Case Presentation
A 53 year-old Caucasian man with unremarkable past
medical history was diagnosed with MM in November
of 2006. He presented with back pain, and MRI of the
spine revealed multiple compression fractures. Skeletal
survey was negative for lytic lesions. Bone marrow aspi-
rate revealed 75% kappa-restricted atypical plasma cells,
establishing the diagnosis of MM. Cytogenetic analysis
was normal, and the translocation t(11;14) was the only
abnormality detected by the MM FISH panel. IFE was
positive for monoclonal IgE-kappa proteins, IgE level
was 5,300,000 IU/mL, serum free kappa was normal,
and Bence-Jones proteinuria was absent. Patient received
treatment with multiple regimens, which included dexa-
methasone, thalidomide, bortezomib, and lenalidomide.
However, 28 months after the diagnosis, MM became
refractory to those agents, and patient was referred to
our Institution for autologous stem cell transplantation.
Our review of the peripheral smear showed circulating
atypical plasma cells, representing 52% of the WBC
(12,600/μL), and we made the diagnosis of secondary
PCL. Bone marrow aspirate contained 80% plasma cells,
harboring the original cytogenetic features. At flow
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and negative for CD56 and CD20. Initially, serum level
of IgE was reported as normal, but a distinct M peak
was present on SPEP. The result of the IgE level was
f o u n dt ob ef a l s e l yn o r m a ld u et ot h e“prozone effect”.
Our laboratory observed the paradoxical increase of the
IgE levels with progressively increasing dilutions of the
serum sample (Figure 1). Capillary zone electrophoresis
for SPEP and serum immunotyping was performed by
the Capillarys 2 capillary method (Sebia Electrophoresis,
Norcross GA). Serum IgE levels were measured by the
Siemens Immulite 2000® (Flanders NJ), using the Total
IgE method. All serum IgE dilutions were performed
manually, using the manufacturer’s diluent.
In view of the plasma cell leukemia, we elected to
proceed with an allogeneic instead of autologous trans-
plantation. After induction therapy with 2 cycles of
VDT-PACE (bortezomib, dexamethasone, cisplatin, dox-
orubicin, cyclophosphamide, and etoposide, given at the
doses and schedule described elsewhere [11]), patient
underwent a non-myeloablative allogeneic stem cell
transplantation from his HLA-identical sister, using flu-
darabine and cyclophosphamide as conditioning regi-
men. The post-transplant evaluation at day 100 revealed
full hematologic recovery, absence of circulating plasma
cells in the peripheral blood -even by flow cytometry-,
no evidence of graft-vs-host-disease, and MM in partial
remission by serum M component and bone marrow
biopsy. Monitoring of disease response during the
treatment was based on the quantification of the serum
M at SPEP, because IgE levels were found to be inaccu-
rate and erratic (Table 1).
Conclusions
PCL is distinguished in “primary PCL”,w h i c ho c c u r sa s
ad en o v op r e s e n t a t i o no ft h el e u k e m i a ,a n d“secondary
PCL”, which is the leukemic transformation of a pre-
viously diagnosed MM. Our patient had the secondary
form, because it developed 28 months after the initial
diagnosis of MM. To our knowledge, 8 other cases
of IgE-producing PCL have been reported in the
medical literature, and only 2 of them were secondary
PCL [12,13]. The incidence of high-risk chromosomal
abnormalities, such as complex karyotype and monos-
omy 13, is high in patients with secondary PCL [14].
However, in our patient, malignant plasma cells both in
peripheral blood and BM displayed the same cytogenetic
abnormalities observed at baseline, i.e., only the translo-
cation t(11;14)(q13;q32) at FISH, and no other chromo-
somal aberrations. Of note, the t(11;14) translocation is
considered a hallmark of IgE, IgM, and nonsecretory
MM, all rare subtypes of MM [15]. Interestingly, a
recent publication described a case of IgE MM asso-
ciated with very high serum levels of serum CA125
(1292.3 U/mL) [16], a tumor marker expressed in var-
ious cancers, including ovarian carcinoma and hemato-
logic malignancies [17]. We did not confirm this
association in our patient, because his serum CA125
level before induction therapy was 17.9 U/mL, within
normal limits (0-34 U/mL).
An important aspect of our case was the unreliability
of quantitative IgE levels in the assessment of disease
response, due to the prozone effect. Response to therapy
in our case was best monitored with the quantification
of the M component at SPEP. The recent introduction
Figure 1 Immulite® readings of multiple serial dilutions of the
same sample showing prozone effect. The calculated
concentration of IgE based on the final measured reading times the
dilution factor is plotted along the X axis against the actual
instrument reading (counts per second) along the Y axis. Both axes
are logarithmic and the dilutions that were used were 1:100,000,
1:10,000, 1:1000, 1:100, and undiluted. In parenthesis at each dilution
point is the reading reported by the instrument. The dotted line
represents the highest reported value of 2000 IU/mL. The lines
connecting each point are for illustration and do not represent the
actual values at intermediate dilutions.
Table 1 Erratic serum levels of IgE during the response of
MM/PCL after allogeneic stem cell transplantation
DAY Serum
M component
(g/dL)
Serum IgE
(I.U./mL)
-64 1.6 19,280,000
-48 1.3 —
-29 1.2 14,110,000
-8 0.4 14,233,000
+15 0.4 115,000,000
+21 0.4 —
+35 0.4 —
+49 0.4 2,910,000
+89 0.4 23,700,000
Day -64 is the first day of induction chemotherapy, and day 0 is the day of
allogeneic stem cell transplantation.
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has offered another useful tumor marker for monitoring
response to therapy in MM [18]. Due to the rarity of
IgE MM, no sufficient data of the use of FLC in this
subtype of MM are available. In our patient, the serum
FLC assay had no role in assessing response to therapy,
because the serum free kappa level was always within
normal limits.
The prozone effect is a laboratory phenomenon that
occurs when antigen excess interferes with antibody-
based methods requiring immune complex formation
for detection. For immunometric immunoassays, detec-
tion of the analyte (in this case, serum IgE) requires that
each molecule binds to two separate reagent antibodies
in an antibody-analyte-antibody complex: one antibody
that “captures” the antigen and the second that provides
a detection signal. With excessive amounts of analyte,
each reagent antibody binds to separate analyte mole-
cules, not forming the complex essential for detection.
T h ep r e s e n c eo ft h i s“high-dose hook” effect should be
suspected when the result on a diluted sample is higher
than in the undiluted sample. The prozone effect is a
well know phenomenon that may complicate the inter-
pretation of various quantitative assays, including those
for IgG and IgA [19,20], and laboratory protocols to
avoid it have been proposed [19]. The elevations that
produce such results are so high that significant manual
dilutions are required to bring the concentration into
the reporting range of the instrument, and dilution
errors are common. For this patient, a 1:10,000 or
1:100,000 dilution was required to obtain a reading, a
difficult task even for experienced bench personnel. The
variability in serum IgE levels shown in Table 1 may be
explained by the challenge of diluting each sample a
minimum of 10,000 fold, when standard medical labora-
tory techniques rarely require a dilution greater 1:100. It
is important to recognize the presence of a prozone
effect, because it can produce falsely normal results.
Due to this effect, the use of only IgE levels for monitor-
ing the response to therapy in our patient could have
led the clinicians to inappropriate interpretations of the
results and possible therapeutic mismanagement.
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